Amgen
Potential of an Investigational Gene Therapy to Treat Fabry Disease. Click Here to See if You Qualify to Join the Study!
- See If You Qualify Today
Find out if you qualify for our
clinical trial.
- Contact Us
Contact us for more information
about our Sangamo study.
- Diagnosed With Fabry?
Exploring The Potential of New
Gene Therapy For Fabry Disease
- Fabry Disease
Learn more about
Sangamo Fabry
- Glossary
Learn More About Our
Extensive Glossary.
- Study Overview
Learn more about the Sangamo
Fabry Clinical Study
- See If You Qualify Today
Search results
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
- Responsibility
The CoLab, previously the Biogen Community Lab, is a...
- Alzheimer's Disease
Biogen’s commitment to health equity is rooted in efforts...
- Amyotrophic Lateral Sclerosis
Kate was busy planning her wedding when she was diagnosed...
- Lupus
Biogen’s decades of study at the crossroads of neurology and...
- Multiple Sclerosis
Multiple sclerosis (MS) is a complex, heterogeneous, chronic...
- Spinal Muscular Atrophy
SMA, an inherited disease that can have a devastating effect...
- Pipeline
Breaking New Ground With Science. With a strong focus on...
- News Releases
Biogen and Delta Flight Products to Collaborate with...
- Responsibility
Founded in 1978, Biogen has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease.
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan ...
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
Breaking New Ground With Science. With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients and protect public health.
Biogen is a global company that discovers, develops and delivers innovative therapies for neurological and neurodegenerative diseases. Founded in 1978, Biogen has a leading portfolio of medicines for multiple sclerosis, spinal muscular atrophy and other neuroscience fields.
Jun 7, 2021 · Biogen's aducanumab is the first medication to slow cognitive decline in Alzheimer's patients in nearly two decades. The FDA granted approval with a condition that Biogen conduct another clinical trial, while the drug's price is $56,000 per year.
People also ask
Who is Biogen & why should you care?
Who is Biogen?
Is Biogen a stock?
Is Biogen a drug candidate?
